12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Therascreen EGFR Mutation Detection Kit RGQ regulatory update

FDA approved a PMA from Qiagen for therascreen EGFR Mutation Kit to identify patients with EGFR mutation-positive tumors. The test is a companion diagnostic for Gilotrif afatinib...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >